PubRank

R Iggo

Author PubWeight™ 46.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990 6.34
2 Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990 3.89
3 Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993 2.40
4 Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 1992 2.07
5 Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 1996 1.75
6 A rapid PCR fidelity assay. Nucleic Acids Res 1994 1.47
7 Increased apoptosis induction by 121F mutant p53. EMBO J 1999 1.41
8 Autoregulation of expression of the yeast Dbp2p 'DEAD-box' protein is mediated by sequences in the conserved DBP2 intron. EMBO J 1995 1.28
9 The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996 1.27
10 p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001 1.20
11 Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 1997 1.12
12 SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 2007 1.10
13 Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997 1.09
14 Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999 1.07
15 Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 1996 1.06
16 Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J 1994 1.03
17 Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008 0.96
18 A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet 1999 0.90
19 Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001 0.89
20 A photosensitising adenovirus for photodynamic therapy. Gene Ther 1999 0.88
21 Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 1996 0.88
22 High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997 0.88
23 Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001 0.87
24 Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002 0.84
25 Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 1998 0.84
26 Asymmetric PCR-based strategy for genetic analysis of the p53 tumor suppressor gene in cell lines and tumor tissues. Neoplasma 1991 0.83
27 Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis 1997 0.82
28 Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology. Oncogene 1997 0.81
29 Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. Cancer Gene Ther 2006 0.81
30 Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 1997 0.80
31 Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 1998 0.80
32 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther 2004 0.80
33 Identification of clonal mutations in morphologically normal mucosa of the aerodigestive tract. Eur J Cancer Prev 1996 0.79
34 Retrovirus-mediated p53 gene therapy. Nat Med 1996 0.77
35 Homozygous p53 gene mutation in a radiation-induced glioblastoma 10 years after treatment for an intracranial germ cell tumor: case report. Neurosurgery 1997 0.77
36 p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002 0.77
37 Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res 1998 0.76
38 Overcoming complexities in genetic screening for cancer susceptibility. Cold Spring Harb Symp Quant Biol 1994 0.75